

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the antibody drug JMT203 (the “**Product**”) independently developed by Shanghai JMT-Bio Technology Co., Ltd.\* (上海津曼特生物科技有限公司), a subsidiary of the Company, has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a Class 1 innovative drug independently developed by the Group for the treatment of cancer cachexia. It is a recombinant humanized monoclonal antibody against GDNF family receptor alpha like (GFRAL), which can effectively antagonize the GDF15-GFRAL/RET signal and regulate appetite and metabolism. It can potentially reverse or reduce cachexia symptoms such as weight loss, anorexia and muscular dystrophy caused by tumors and chemotherapy drugs, thereby effectively improving the quality of life of tumor patients. The preclinical studies have demonstrated that the Product has good safety profile, and is able to significantly inhibit weight loss, increase non-fasting blood glucose and improve the forepaw grip strength of cachexia mouse, thereby relieving the cachexia symptoms and improving the tumor-bearing survival rate of cachexia mouse, and significantly increase the treatment tolerance and extend survival in combination with anti-tumor therapies.

The Product is the first anti-GFRAL antibody obtaining clinical trial approval in China. Currently, GDF15 or GFRAL target drugs are in the early stage of clinical development worldwide with no such drugs available in the market. The Product has the potential to become an effective drug for the treatment of cancer cachexia, providing a promising clinical development value.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 26 June 2023

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*

*\* For identification purposes only*